Skip to main content

Y-mAbs Therapeutics, Inc.

YMABDelisted Sep 16, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001722964

Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Y-mAbs Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Y-mAbs Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Y-mAbs Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hamill LauraDirector0Sep 19, 20250
Gill David NDirector0Sep 18, 20250
Healy JamesDirector0IndirectSep 18, 20250
Pfreundschuh Peter P.EVP, CFO and Treasurer0Sep 18, 20250
LaRocca JohnSVP, General Counsel & Secry0Sep 18, 20250
Tyagi AshuDirector0Sep 18, 20250
Wedell-Wedellsborg JohanDirector, 10% Owner0IndirectSep 18, 20250
WG Biotech ApSDirector, 10% Owner0Sep 18, 20250
Gad ThomasCHIEF BUSINESS OFFICER0IndirectSep 18, 20250
Wilms JorisSVP & CHIEF OPERATING OFFICER0Sep 18, 20250
Rossi Michael JPRESIDENT & CEO0Sep 18, 20250
Gentilcore Douglas JSVP, Danyelza Bus. Unit Head–Sep 18, 20250
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICER35,600Aug 30, 20240
Tagliaferri MaryDirector8,155Jun 13, 20240
Ber GerardDirector1,608Jun 11, 20240
Kruse BoEVP, CFO, SECRY & TREAS.210,877May 31, 20240
Rajah VigneshSVP & CHIEF MEDICAL OFFICER33,889Mar 7, 20240
Smith Susan LauraSVP & CHIEF COMMERCIAL OFFICER33,918Mar 7, 20240
Lisby SteenSVP & CHIEF SCIENTIFIC OFFICER35,600Jan 22, 20240
Moller-San Pedro Claus JuanDirector and CEO–Dec 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 23, 2021 (view filing)Sep 221 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$30.82−$123.3K−1.8%221.1K after
Sep 17, 2021 (view filing)Sep 152 daysGad ThomasSee remarksSSale−4.00K$33.64−$134.6K−0.3%1.50M after
Sep 8, 2021 (view filing)Sep 71 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$32.03−$128.1K−1.7%225.1K after
Sep 7, 2021 (view filing)Sep 25 daysGad ThomasSee remarksSSale−50.0K$33.18−$1.66M−3.2%1.50M after
Aug 24, 2021 (view filing)Aug 231 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$28.60−$114.4K−1.7%229.1K after
Aug 17, 2021 (view filing)Aug 13-174 daysGad ThomasSee remarksSSale−29.0K$29.35−$851.0K−1.8%1.55M after4 lots
Aug 13, 2021 (view filing)Aug 121 dayRajah VigneshSVP & CMOPPurchase+1.37K$29.95+$41.2K+81.0%3.07K after
Aug 5, 2021 (view filing)Aug 41 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$33.72−$134.9K−1.7%233.1K after
Aug 5, 2021 (view filing)Aug 32 daysGad ThomasSee remarksSSale−4.00K$33.73−$134.9K−0.3%1.58M after
Jul 26, 2021 (view filing)Jul 224 daysKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$34.50−$138.0K−1.7%237.1K after
Jul 21, 2021 (view filing)Jul 201 dayGad ThomasSee remarksSSale−4.00K$32.47−$129.9K−0.3%1.59M after
Jul 8, 2021 (view filing)Jul 71 dayGad ThomasSee remarksSSale−4.00K$31.87−$127.5K−0.3%1.59M after
Jul 7, 2021 (view filing)Jul 61 dayKruse BoEVP, CFO, Secretary & Treas.SSale−4.00K$34.15−$136.6K−1.6%241.1K after
Jul 2, 2021 (view filing)Jun 302 daysGad ThomasSee remarksSSale−4.00K$33.86−$135.4K−0.3%1.60M after